Corrigendum to: "Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder" [Eur Urol 2007;52:1204-12] (DOI:10.1016/j.eururo.2007.07.009);Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

European Urology

Volumn 52, Issue 4, 2007, Pages 1204-1212

  Chapple, Christopher ^a   Van Kerrebroeck, Philip ^b   Tubaro, Andrea ^c   Haag Molkenteller, Cornelia ^d   Forst, Hans Theo ^d   Massow, Ute ^d   Wang, Joseph ^e   Brodsky, Marina ^e  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Schwarz Pharma AG   (Germany)

^e PFIZER INC   (United States)

Author keywords

Fesoterodine; Micturitions; OAB; Urgency incontinence

Indexed keywords

FESOTERODINE; FLAVOXATE; OXYBUTYNIN; PLACEBO; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY THROAT; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; URINARY FREQUENCY; URINE RETENTION; XEROSTOMIA;

EID: 34548291010     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.086     Document Type: Erratum

References (20)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
2. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
3. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315
4. Moreland R.B., Brioni J.D., and Sullivan J.P. Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. J Pharmacol Exp Ther 308 (2004) 797-804
5. Nitti V, Wiatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Paper presented at International Continence Society, Montreal, Canada, August 31-September 2, 2005.
6. Cawello W., Auer S., Hammes W., Sachse R., and Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects [abstract]. Naunyn Schmiedebergs Arch Pharmacol 365 Suppl 1 (2002) 428
7. Tubaro A., and De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update Series 2 (2004) 161-169
8. Homma Y., Paick J.S., Lee J.G., and Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 92 (2003) 741-747
9. van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
10. Siami P., Seidman L.S., and Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 24 (2002) 616-628
11. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs of the Future 29 (2004) 715-720
12. Coyne K.S., Matza L.S., Kopp Z., and Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079-1086
13. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26
14. Garely A.D., and Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 27 (2004) 1043-1057
15. ® (oxybutynin chloride). Full prescribing information. Mountain View (CA): ALZA Corporation; 1998.
16. Detrol L.A. (Tolterodine tartrate extended release capsules). Full prescribing information (2003), Pharmacia & Upjohn Company, Kalamazoo (MI)
17. ® (Solifenacin succinate). Full prescribing information. Norman (OK): Yamanouchi Pharma America, Inc, and GlaxoSmithKline; 2004.
18. ® (Darifenacin). Full prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2004.
19. Wallis R.M., and Napier C.M. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 64 (1999) 395-401
20. Schagen van Leeuwen J.H., Castro R., Busse M., and Bemelmans B.L. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50 (2006) 440-453